Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Pravastatin activates eNOS, provides additional clinical benefits

April 7, 1999

All rights to INFeD return to Schein

April 6, 1999

Regeneron and P&G initiate diabetes-associated obesity trial of Axokine

April 6, 1999

FDA approval granted for BioTime's blood plasma volume expander

April 6, 1999

Potent, orally active glucagon antagonist developed at Merck & Co.

April 6, 1999

Potent, selective human beta3-AR agonist characterized by Merck & Co.

April 6, 1999

Patent issued for new Merck glucagon antagonists

April 5, 1999

Inhibitors of the formation of AGTs described by Alteon

April 5, 1999

AMBI's Chromax demonstrates safety and efficacy in treatment of diabetes

April 5, 1999

Aradigm issued method patent for pulmonary insulin delivery

April 5, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...